Skip to main content
NIH funding notice PAR-24-037

HIV Vaccine Research and Design (HIVRAD) Program (P01 Clinical Trial Not Allowed)

Closed on March 13, 2026.

Posted
October 4, 2023
Close date
March 13, 2026
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $3,552,620 in first-year total cost, median $3,552,620.

Most frequent study sections

  1. Special Emphasis Panel[ZAI1 BJM-A (S1)]1

Most frequent institutions

  1. UNIVERSITY OF CALIFORNIA AT DAVIS1
Competing awards under PAR-24-037 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2025Optimal T-cell support for HIV neutralizing antibody induction to fusion peptide-inclusive regimens (Opti-FliP)1P01AI181044-01A1HARTIGAN-O'CONNOR, DENNIS J.UNIVERSITY OF CALIFORNIA AT DAVIS, CA$3,552,620ZAI1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.